These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25156648)

  • 21. Irreversible Electroporation for Colorectal Liver Metastases.
    Scheffer HJ; Melenhorst MC; Echenique AM; Nielsen K; van Tilborg AA; van den Bos W; Vroomen LG; van den Tol PM; Meijerink MR
    Tech Vasc Interv Radiol; 2015 Sep; 18(3):159-69. PubMed ID: 26365546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors.
    Bäumler W; Schicho A; Schaible J; Verloh N; Senk K; Wiggermann P; Stroszczynski C; Beyer LP
    PLoS One; 2020; 15(11):e0242093. PubMed ID: 33201902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a robotic system for irreversible electroporation (IRE) of malignant liver tumors: initial results.
    Beyer LP; Pregler B; Michalik K; Niessen C; Dollinger M; Müller M; Schlitt HJ; Stroszczynski C; Wiggermann P
    Int J Comput Assist Radiol Surg; 2017 May; 12(5):803-809. PubMed ID: 27653615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic Resonance Imaging Findings After Percutaneous Irreversible Electroporation of Liver Metastases: A Systematic Longitudinal Study.
    Barabasch A; Distelmaier M; Heil P; Krämer NA; Kuhl CK; Bruners P
    Invest Radiol; 2017 Jan; 52(1):23-29. PubMed ID: 27379698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumors: sensitivity based on comparison with intraoperative and pathologic findings.
    Kuszyk BS; Bluemke DA; Urban BA; Choti MA; Hruban RH; Sitzmann JV; Fishman EK
    AJR Am J Roentgenol; 1996 Jan; 166(1):91-5. PubMed ID: 8571914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual-phase helical CT of the liver: value of arterial phase scans in the detection of small (< or = 1.5 cm) malignant hepatic neoplasms.
    Hollett MD; Jeffrey RB; Nino-Murcia M; Jorgensen MJ; Harris DP
    AJR Am J Roentgenol; 1995 Apr; 164(4):879-84. PubMed ID: 7726040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irreversible electroporation for the ablation of liver tumors: are we there yet?
    Charpentier KP
    Arch Surg; 2012 Nov; 147(11):1053-61. PubMed ID: 23165618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percutaneous irreversible electroporation of hepatocellular carcinoma: Contrast-enhanced ultrasound-findings during 1-year follow-up.
    Niessen C; Beyer LP; Haimerl M; Schicho A; Stroszczynski C; Wiggermann P; Jung EM
    Clin Hemorheol Microcirc; 2019; 72(1):85-93. PubMed ID: 30584122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Color Coded Perfusion Imaging with Contrast Enhanced Ultrasound (CEUS) for Post-Interventional Success Control Following Irreversible Electroporation (IRE) of Primary and Secondary Malignant Liver Lesions.
    Rennert J; Wiesinger I; Schicho A; Wiggermann P; Stroszczynski C; Beyer LP; Jung EM
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):311-318. PubMed ID: 31517328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrasound and Contrast-enhanced Ultrasound Findings after Percutaneous Irreversible Electroporation of Hepatic Malignant Tumors.
    Chai W; Xie L; Zhao Q; Cheng C; Tian G; Jiang T; Wu P
    Ultrasound Med Biol; 2020 Mar; 46(3):620-629. PubMed ID: 31924420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic tumors treated by cryosurgery: normal CT appearance.
    Kuszyk BS; Choti MA; Urban BA; Chambers TP; Bluemke DA; Sitzmann JV; Fishman EK
    AJR Am J Roentgenol; 1996 Feb; 166(2):363-8. PubMed ID: 8553949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of pattern classification 24 hours after radiofrequency ablation of liver metastases on CT and positron emission tomography/CT.
    Vandenbroucke F; Vandemeulebroucke J; Ilsen B; Verdries D; Belsack D; Everaert H; Buls N; Ros PR; de Mey J
    J Vasc Interv Radiol; 2014 Aug; 25(8):1240-9. PubMed ID: 24954606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging.
    Kim CK; Choi D; Lim HK; Kim SH; Lee WJ; Kim MJ; Lee JY; Jeon YH; Lee J; Lee SJ; Lim JH
    Eur J Radiol; 2005 Oct; 56(1):66-73. PubMed ID: 15913940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcatheter CT arterial portography and CT hepatic arteriography for liver tumor visualization during percutaneous ablation.
    van Tilborg AA; Scheffer HJ; Nielsen K; van Waesberghe JH; Comans EF; van Kuijk C; van den Tol PM; Meijerink MR
    J Vasc Interv Radiol; 2014 Jul; 25(7):1101-1111.e4. PubMed ID: 24755086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up.
    Dromain C; de Baere T; Elias D; Kuoch V; Ducreux M; Boige V; Petrow P; Roche A; Sigal R
    Radiology; 2002 Apr; 223(1):255-62. PubMed ID: 11930075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semiautomated versus manual evaluation of liver metastases treated by radiofrequency ablation.
    Keil S; Bruners P; Ohnsorge L; Plumhans C; Behrendt FF; Stanzel S; Sühling M; Günther RW; Das M; Mahnken AH
    J Vasc Interv Radiol; 2010 Feb; 21(2):245-51. PubMed ID: 20123208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percutaneous Irreversible Electroporation (IRE) of Hepatic Malignancy: A Bi-institutional Analysis of Safety and Outcomes.
    Mafeld S; Wong JJ; Kibriya N; Stenberg B; Manas D; Bassett P; Aslam T; Evans J; Littler P
    Cardiovasc Intervent Radiol; 2019 Apr; 42(4):577-583. PubMed ID: 30465255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy.
    Scheffer HJ; Nielsen K; de Jong MC; van Tilborg AA; Vieveen JM; Bouwman AR; Meijer S; van Kuijk C; van den Tol PM; Meijerink MR
    J Vasc Interv Radiol; 2014 Jul; 25(7):997-1011; quiz 1011. PubMed ID: 24656178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular carcinoma: the role of helical biphasic contrast-enhanced CT versus CT during arterial portography.
    Kanematsu M; Oliver JH; Carr B; Baron RL
    Radiology; 1997 Oct; 205(1):75-80. PubMed ID: 9314965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detecting hepatocellular carcinoma: value of unenhanced or arterial phase CT imaging or both used in conjunction with conventional portal venous phase contrast-enhanced CT imaging.
    Oliver JH; Baron RL; Federle MP; Rockette HE
    AJR Am J Roentgenol; 1996 Jul; 167(1):71-7. PubMed ID: 8659425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.